Phathom Pharmaceuticals (PHAT) Current Deferred Revenue: 2023-2025
Historic Current Deferred Revenue for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Sep 2025 value amounting to $24.3 million.
- Phathom Pharmaceuticals' Current Deferred Revenue rose 20.55% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 20.55%. This contributed to the annual value of $19.8 million for FY2024, which is 178.12% up from last year.
- Per Phathom Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $24.3 million for Q3 2025, which was up 13.09% from $21.5 million recorded in Q2 2025.
- Phathom Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $24.3 million during Q3 2025, with a 5-year trough of $276,000 in Q2 2023.
- Its 3-year average for Current Deferred Revenue is $13.9 million, with a median of $16.9 million in 2024.
- Data for Phathom Pharmaceuticals' Current Deferred Revenue shows a peak YoY surged of 3,490.58% (in 2024) over the last 5 years.
- Quarterly analysis of 3 years shows Phathom Pharmaceuticals' Current Deferred Revenue stood at $7.1 million in 2023, then spiked by 178.12% to $19.8 million in 2024, then increased by 20.55% to $24.3 million in 2025.
- Its Current Deferred Revenue was $24.3 million in Q3 2025, compared to $21.5 million in Q2 2025 and $17.3 million in Q1 2025.